From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Resource TypeSegment
This is the first in a six-part series exploring the "Gross-to-Net (GTN) Bubble" in the pharmaceutical industry. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
Read Article
In this issue, Bill explains why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
In this issue, Bill makes sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
Ready to capitalize on the booming cash-pay pharmacy market? This webinar provides the roadmap to build a successful cash-pay program.
View Webinar
Remember the days when brand-name drug prices seemed to only go up, year after year, until a generic competitor arrived? Well, 2024 has brought a surprise! We're seeing a surge in wholesale acquisition cost (WAC) cuts across the pharmaceutical industry.
Branded Pharmaceutical Manufacturers from large to emerging are struggling to ensure patients can find pharmacies that are capable and willing of dispensing Gen Med non-specialty brands, which account for 8% of the prescriptions that flow out of the pharmacy. Home Delivery and Digital Pharmacy...
In this issue, Bill analyzes the general portion of the pharmacy market amid ensuing challenges. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
In this issue, Bill provides the baseline framework to help manufacturers and pharmacies understand what is broken with retail pharmacy and what to do about it. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
Unpack the latest changes in State Price Transparency Reporting regulations impacting pharmaceutical manufacturers. Gain clarity on key requirements, emerging trends like increased pricing scrutiny, potential challenges, and best practices for efficient compliance on March 26.
Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.
Bill Roth delves into the dynamic evolution of PBMs and the impactful recent price structure overhauls. Gain valuable insights and stay ahead of the ever-changing landscape of pharmaceuticals.
Bill Roth dives into the impact of Eli Lilly and Company direct-to-consumer digital platform on the market as well as the drivers that prompted it. Watch the video or read the interview from Pharmaceutical Commerce Magazine.
Pharma giants face declining reimbursements, new patient journeys, and entrenched leadership, pushing the industry towards novel pharmacy models. Bill explores the future of pharmaceuticals in this issue.
In this issue, Bill analyzes the two main models for pharmacy - unique direct-to-consumer for brands and cash pay for generics- and what members of the industry think about them. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
Optimize your discounting strategy across payers and channels. Join us for a session on best practices and common pitfalls. Join Jennifer Sharpe and Reena Patel on April 25th to learn more!
Pharmaceutical wholesalers face challenges as generic brands increase, costs rise, and manufacturers seek new distribution models. Managing distribution agreements becomes more complex, affecting accountability and overwhelming teams. Our experts offer trends and best practices for navigating these challenges.
There are a flurry of policies and changing industry dynamics impacting pricing and commercialization strategy. The Inflation Reduction Act, the AMP cap removal on Medicaid Drugs, and the movement to cash certainly impact pricing and access strategies and tactics, but how exactly?
In this issue, Bill delves into the origins of the pharmaceutical industry, highlighting how it initially operated as a cash-based business. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
Increasingly, manufacturers are establishing policies that define 340B pricing eligibility for covered entities who purchase through a contract pharmacy. In order to effectively control revenue leakage, those policies should follow through to downstream chargeback and rebate validation and adjudication. Join us as we discuss...
The growing complexity of managed-markets contract support makes outsourcing a near-necessity for Small Pharma, and a better option for Big Pharma. Read more in Blue Fin Group's Bill Roth's ongoing column in Pharmaceutical Commerce.
Every pharmaceutical company wants an accurate, consistent gross-to-net (GTN) process. However, data discrepancies between ex-factory reporting and wholesaler reporting are just one of many issues that can create GTN inaccuracies. Join IntegriChain product and solution experts to discuss how Inventory Roll Forward management and...
In this 2nd webinar of the series, IntegriChain product and solution experts explore how downstream inventory and demand projection inaccuracies can create havoc with gross-to-net (GTN) processes. Attendees will learn how IntegriChain capabilities can drive more efficient, accurate, and audit-ready GTN results.
This customer had three in-line therapies across Immunology, Hematology, and Infectious Disease with another five therapies in phase III clinical trials. As is the case with many specialty therapies, the level of competition was increasing, driving the need for more aggressive commercial contracting and...
Read Case Study
This customer is one of the world’s largest Pharmaceutical manufacturers with 76 in-line drugs covering more than 100 conditions across 10 therapeutic categories and another dozen drugs in phase 3 clinical trials. Their portfolio is highly diversified, with multiple drug archetypes ranging from traditional...
Success in commercializing generic drugs isn’t easy. The razor-thin profit margins require commercial leaders to have keen visibility into sales, demand, and inventory to ensure sufficient product availability and avoid stockout fees. Additionally, there is little room for revenue leakage, so being able to...
During a standard executive business review (EBR) with a $1B oncolytics manufacture, IntegriChain learned that their customer planned to expand into a new therapeutic category, dermatology. Entering a new category meant moving from smaller data volumes, fewer price concessions, and less government pricing (GP)...
IntegriChain was approached by a customer that was planning to launch a novel, oral therapy targeting 2.4 million patients in the highly generalized and competitive antipsychotic therapy segment. To bring its therapy to market, they would need to contract with both Medicaid and Medicare...
This case study highlights how a top-20 pharma manufacturer has a wide range of specialty, orphan/rare, and traditional brands across more than eight therapeutic categories. As a result of their evolution into precision medicine, their channel data strategies were becoming dated and they had...
This case study highlights how IntegriChain delivered their innovative ICyte Saas Platform to help the manufacturer identify and resolve obstacles.
From the rising costs of distribution and dispensing obstacles to the growing presence of digital pharmacies, direct distribution, and alternative networks, pharmaceutical organizations are trying to pivot in this new environment. IntegriChain and Blue Fin Group channel experts Dave Weiss, Vice President of Industry...
As 340B purchasing through Contract Pharmacies continues to increase year after year, manufacturers are responding through policies that address program integrity of covered entities purchasing through contract pharmacies. Join us as we discuss the history and examples of these initiatives and reactions by industry...
The growth of specialty and specialty-lite drugs means that manufacturers have to contend with channel design and pricing challenges as they approach commercialization and beyond. Join Join Jennifer Sharpe, Vice President of Gross-to-Net Consulting and Reena Patel, Partner at Blue Fin Group as they...
Biosimilars and specialty generics are the new hot ticket for the pharma industry. However, there may be a rocky road ahead. Join Jason Bogroff, Senior Principal, Blue Fin Group where he will explore the trends, strategies and future of biosimilars and specialty generics across...
Our industry continues to grapple with the extensive drug pricing reform components of the Inflation Reduction Act of 2022. Join Jeff Baab and Ben Fanelli as they share some real world examples to illustrate how manufacturers are attempting to operationalize these provisions and account...
Discover Gross-To-Net benchmarks from the Revenue Analytics Collaborative (RAC), looking back on the last seven years of trends and best practices around GTN methodology, automation, and optimization.
Download Paper
Blue Fin Group experts demystify product commercialization and patient funnel questions with consideration of the complexities in today’s market.
An oncolytic manufacturer was about to expand into the dermatology category but was unsure how to develop a commercialization strategy in this new space. With IntegriChain, they gained the insights and operational blueprints necessary for a successful category entry.
Hear from pharma manufacturers in their own words on the time and cost savings they realized with ICyte GTN adoption.
View Infographic
Kerri Fortier and Jonny Clark discuss the evolution of payer management for oncology therapies through a quantitative survey with qualitative in-depth interviews with payers overseeing approximately 238 million commercial, Medicare, and Medicaid lives.
Watch Tim Paine, Principal Consultant at Blue Fin Group as he discusses the 30-year history of the 340B program and its impact on patients, payers, and manufacturers and estimates what the program might look like in the next 10 years.
Join Jen Sharpe, VP of GTN Consulting as she presents the latest insights from the 2022 GTN Benchmark survey, compares trends to previous years and shares best practices to measure your GTN processes.
As the gross-to-net bubble grows each year, so does the complexity of government programs. Learn more about these new regulations and what pharmaceutical manufacturers can do to mitigate risk while increasing GTN confidence and accuracy.
This eBook explains why commercializing rare and orphan disease therapies is often so difficult and how pharma manufacturers can overcome these obstacles.
Download eBook
Learn more about how you can improve patient initiation and adherence with Health System Specialty Pharmacies in the latest whitepaper from Blue Fin Group.
A top 10 pharmaceutical manufacturer had not refreshed their distribution services agreement (DSA) in over a decade and believed it would cost tens of millions of dollars to support their current distribution model-- until they met with Blue Fin Group.
How Blue Fin Group was able to support the product commercialization for a clinical-stage biopharmaceutical company launching their first therapeutic candidate in a new drug class.
How a leading orphan and rare disease product manufacturer was able to meet an identified unmet patient need and respond to its first competitor product.
A top 10 pharmaceutical manufacturer was preparing to launch a complex oncology combination regimen with two novel agents but was faced with several unique commercial challenges.
Selecting a 3PL partner is a critical first step in implementing a product’s channel strategy and ensuring appropriate physical, financial, transactional, and data flows in the market.
Listen to Jeff Baab and Jason Zemcik from TrialCard outline guidance on how industry leaders can build flexible solutions that address a variety of legal, financial, and patient scenarios ahead of the January 1, 2023 effective date for the CMS Final Rule on...
Listen OnDemand to John Whitridge and Olivia Nweze discuss the current status of drug pricing transparency laws that have been recently introduced and updated at the state level. Topics include disclosures themes, types of reports, and new reporting updates for nearly a dozen states.
Listen to Chris Jewell and Haley Morgalo discuss the need for an unblinding solution in the industry, and the new and existing techniques that manufacturers can leverage to gain full visibility into the channel, including downstream inventory levels.
Re-watch Brittany Jen Sharpe at the InformaConnect GTN Show give a glimpse into the mind of a C-Suite executive and underscores the role of GTN accuracy and proficiency to the broader business.
Re-watch Brittany Honeycutt at the InformaConnect GTN Show illustrate current methodologies and company approaches as they relate to prevailing GTN challenges. And, discover platform-centric strategies that are reshaping the landscape for end-to-end GTN success.
With a unifying goal of researching and developing cures for rare diseases for small patient populations, this manufacturer needed to position itself for success with a scalable infrastructure for Market Access. IntegriChain’s unified platform provided the blueprint for the customer’s processes.
Re-watch Jeff Baab, Vice President, Advisory and Rupal Patel, Senior Director, Advisory, review the universe of contracts and programs, discuss initial contracting set up, and provide a checklist of processes and infrastructure steps to follow.
Re-watch James Perry, Senior Product Manager and Brian Coleman, Vice President, Product Management discuss three separate use cases in implementing a claims level detail (CLD) strategy to increase visibility, reduce revenue leakage and support the rebate management function.
If you’re having trouble assembling your vision for market access success, you don’t have to do it alone. IntegriChain has helped launch more than 120 brands in the past 3 years, including more than 40 first time launches. We have the data, benchmarks, and...
IntegriChain’s Benchmark Advisory service helps market access, contracting, distribution/trade, and patient services professionals in pharmaceutical manufacturers, large and small, achieve confidence in their channel designs, contracting strategies, and gain deeper insight into which providers and pharmacies are critical to ensuring therapies reach the right...
Watch Jen Sharpe and Brittany Honeycutt present The Platform-Centric Approach to GTN Success at the Accounting and Reporting Congress 2021 with Agile Therapeutics, SK Life Sciences, and Ironshore Pharmaceuticals. They discuss: Digitalizing revenue management, Reporting and analytics, Patient distribution and GTN management, Patient journey...
Watch Angelina Pigna sit down with Kary Callahan of Paratek and Melanie Morel-Ferris of Relay Therapeutics and discuss all the steps to a successful GTN launch, including methodology design, copay and coverage gap models and accrual management.
As the GTN bubble grows, so does increased stakeholder scrutiny on GTN analytics. GTN automation may not be the first priority for life sciences manufacturers today, but all signs point to GTN automation being the wave of the future.
State Price Transparency legislation is a response to the industry trend of increasing Wholesale Acquisition Cost (WAC) prices and the lack of public knowledge around the reasoning for those increases. Individual states have taken it upon themselves to take legislative action in order to...
Re-watch Jen Sharpe, Executive Director, Gross-to-Net Solutions of IntegriChain, Kary Callahan, Director, Commercial Finance of Paratek, and Tina Knell, Assistant Director, Revenue of BridgeBio present the Case Study: Real World GTN Transformation using Data and Analytics, at InformaConnect's BioPharma CFO Digital Week.
A life sciences manufacturer recently launched their first product and faced many challenges along the way. They knew that in order to maximize market access success, they needed a technology partner who was flexible enough to help them scale and adjust for their specific...
Listen to Josh Halpern, Co-Founder & Executive Vice President, Product & Strategy, and Azeem Ahmed, Director, Industry Solutions - Patient Access discuss how the role of data aggregator is undergoing a transformation from tactical departmental solution to an essential backbone of commercialization.
In order to ensure a smooth patient journey and eliminate potential barriers to therapy initiation and adherence, specialty pharmaceutical manufacturers depend on accurate, detailed, and timely patient status updates and dispense data from their specialty pharmacy and hub partners. One of the most mysterious...
As you well know, patient adherence to therapy continues to be a challenge for manufacturers. New complex patient journeys and multi-channel brand distribution models make it increasingly difficult to address patient barriers to adherence. If you’re like most manufacturers, you’re heavily invested in patient...
In the past year, COVID-19 has expedited efforts for pharmaceutical manufacturers to adopt improved and automated solutions to accurately manage their Gross-to-Net (GTN) forecasting and accrual processes.
Join Dave Weiss, Vice President, Industry Solutions and Shivani Patel, Director, Advisory Services in the webinar INSIGHTS SERIES - Trends in Vaccine and Anti-Viral Drug Distribution and Channel Insights to learn latest observations and learnings from the initial COVID-19 vaccine and therapeutics rollout, trends...
Learn how IntegriChain applied machine learning and data science to help a major pharmaceutical manufacturer gain deep insight into the timing, cost, and effectiveness of patient intervention programs.
Learn how a fast-growing manufacturer of precision medicines leveraged a unified patient and channel data solution to realize improved channel performance and create a common platform for all future launches, regardless of network design or complexity
Join Rupal Patel, Director of Advisory Services, and John Whitridge, Senior Advisory Services Consultant in our The Current State of Drug Pricing Transparency webinar. In this informative discussion, we will discuss the current state of drug pricing transparency laws, including: what manufacturers can do now...
An emerging manufacturer of rare disease therapies had moved beyond launch and was now looking to improve market access decision support and reduce pricing exposure while maintaining cost-effective operations. Learn why IntegriChain's ICyte platform was the answer.
With a growing population of program participants, the amount of Claim Level Data (CLD) will continue to grow exponentially. Invoice level validations alone cannot bring to light all the potential disputes in the Medicaid data. Without a solid CLD strategy in place, manufacturers are...
Join Jen Sharpe, GTN lead and facilitator of the Revenue Analytics Collaborative at IntegriChain, and Angelina Pigna, Director of Advisory Services in our Gross-to-Net Assessment webinar to receive the results of our recent GTN assessment survey. We’ll share industry expertise and practices for you...
An emerging life sciences manufacturer was planning to launch a novel, oral therapy targeting 2.4 million patients in the highly genericized and competitive antipsychotic market. To bring its therapy to market, they would need to contract with both Medicaid and Medicare programs as well...
Companies large and small are increasingly looking for ways to "do more with less" and achieve both greater efficient and effectiveness of their contracting, pricing, and gross-to-net operations. This webinar will highlight the rationale behind augmenting your market access strategy with managed services.
Creating and optimizing both network design and reimbursement strategies can be a challenge for companies of all size and complexity. In this webinar, you'll learn how to leverage aggregated and refined channel data to improve readiness for successful product launches. Register for our webinar...
In Five Steps to GTN Implementation Success, members of the IntegriChain Implementation team will discuss the benefits of having revenue management software in place on day one and also share customer case studies and best practices for success. Having supported more than 70% of...
For many pharmaceutical manufacturers, leveraging a trusted managed services team is the difference between keeping your head above water or creating an informed, successful market access strategy from your existing data. In this ebook, we discuss the marketplace challenges, risks, and rewards of leveraging...
Join Jen Sharpe, GTN lead and facilitator of the Revenue Analytics Collaborative at IntegriChain, and Tina Knell, Director of Revenue at Akcea, for an in-depth webinar on the Top 10 mission-critical activities for life sciences companies approaching commercial launch.
You can bring more actionable insights and service accountability to your specialty pharmacy relationships with the use of extensive benchmark data. By analyzing these insights, you can easily define each specialty brand’s unique patient access and tailor your business decisions to model unique brand...
This case study highlights how a pharmaceutical manufacturer leveraged IntegriChain data solutions to improve business agility, channel performance, and accuracy of field compensation payments.
Mid-market and large Life Sciences enterprises share a common vision for their technology and commercial insights roadmaps to achieve operational excellence. In this session, we examine the strategic business case for transitioning aging on-premises revenue management to the cloud for best-of-breed pricing and adjudication...
GTN automation, the most critical financial challenge for Life Sciences manufacturers, can improve margins, reduce costs, and mitigate risk by delivering one accurate version of the GTN truth throughout your organization. In this session, we will introduce our newest product and the first major...
This case study focuses on a pharmaceutical manufacturer who, despite using an established third-party logistics (3PL) provider, was struggling with both inconsistent channel data as well as the lack of visibility into downstream inventory. Read how they resolved these issues by partnering with IntegriChain...
See how IntegriChain helped an emerging life science manufacturer launch a novel, oral-based therapy targeting a population of 2.4 million patients.
For many emerging pharmaceutical companies, designing a Gross-to-Net (GTN) organization, is a tremendous challenge. Learn how IntegriChain can help.
Crafting an executing a winning market strategy takes tremendous insight, efficient teamwork and crisp decision-making. Learn how IntegriChain can help.
This paper has highlights the fact that invoice level validations alone cannot bring to light all the potential disputes in the Medicaid data. Without at least some level of use of CLD in your Medicaid process, manufacturers are prone to significant revenue leakage. Download...
This case study highlights how IntegriChain delivered payer data solutions to help the manufacturer identify and resolve obstacles to patient access. As their market access needs evolved to contracting, channel, and gross-to-net, IntegriChain had the optimal solution.
This case study highlights how IntegriChain partnered with an emerging manufacturer and provided the commercialization platform necessary for Day 1 readiness.
This eBook identifies ways in which aggregated, refined, and analyzed channel data can be used to dramatically improve market access.
This eBook identifies the four primary causes of specialty pharmacy (SP) data quality issues and outlines areas for improvement
As the MDSI organization matured, gaps in syndicated DDD and 867 data as well as the risks posed to key strategic business decisions were identified. Trends toward more incomplete coverage data caused by missing 867 data elements and their impact on sales operations became...
This study highlights why and how an innovative manufacturer abandoned their silo-oriented approach to market access and moved to IntegriChain's ICyte platform.
CGT companies seeking to maximize success for newly launched therapies understand that Gross-to-Net (GTN) – when done right – can improve patient access to therapies while driving revenues. This webinar focuses on mission-critical GTN activities for cell and gene therapy companies planning for commercial...
Join us at our new webinar: CMS Proposed Rule - Exploring the Potential Impact to Manufacturers. This webinar will be hosted by Rupal Patel, Director, Advisory Services and Carmela Crimeni, Director, Advisory Services. In this webinar, we will attempt to demystify the potential impact...
The latest ICyte Platform Summer Release is all about data actionability. We’ve now made it easier than ever to provide better, deeper visibility into your data within our single access platform so you can proactively simplify your everyday tasks and spend less time dealing...
Read Blog Post
Increasingly, pharmaceutical manufacturers are realizing that an effective and efficient market access strategy requires careful and coordination management of contracts, pricing, channel and patient data, patient services and gross-to-net processes. Traditionally, this has been performed by different parts of the organization with limited sharing...
Cell and Gene Therapy companies have unique pricing and contracting strategies that can impact government program access. Join IntegriChain’s Jeff Baab and as the do a “deep-dive” into contracting strategies and considerations. Topics to be explored include: Key market considerations, such as payer coverage and...
This paper will focus on IntegriChain's solutions for data stewardship and analytics, with an emphasis on the improved operational benefits pharmaceutical manufacturers can realize in working with their specialty pharmacy partners.
Join us at our new webinar: Considerations for Operationalizing Claim Level Validation (CLD) in Medicaid Rebate Processes. This webinar will be hosted by Manish Rathod, Segment Lead, Contracts and Pricing, James Perry, Manager, Product Development - Medicaid Rebates and Medicaid CLD, and Chad...
Readying for the Government and Commercial Channels is an important launch preparedness step for CGT companies. This webinar from IntegriChain expert Jeff Baab will present crucial contracts and pricing timelines and milestones to get contracts in place for Day 1 readiness. Additional topics to...
Read how IntegriChain's market access platform and vision was the perfect match for this innovative manufacturer of dermatologic therapies.
This eBook highlights a market-tested, 5-step process for ensuring Day 1 readiness for launch.
One of the data quality challenges that we’ve been tackling here at IntegriChain is an issue that really seems to be resonating with life sciences access teams lately: data quality concerns around patient identifiers or patient mastering. We have spent a lot of our...
Join us in our third part of our COVID-19 webinar series. This event will focus on updates plus new investigations in the dynamics of specialty brands from a channel and patient journey perspective. In other words we’ll look into demand and supply trends but...
Join us for this webinar where we will be sharing the challenges with patient mastering and how technological innovations can handle missing data, spelling mistakes and other data errors. Learn how to identify and solve inaccurate patient data!
This case study shows how an emerging pharmaceutical manufacturer partnered with IntegriChain to ensure Day 1 readiness for their new therapy.
This white paper focuses on the Top 10 Gross-to-Net Accounting Practices for Successful Product Launches in the Life Sciences Industry.
Join us in our second part of our COVID-19 webinar series. This event will focus on updates plus new investigations in the dynamics of specialty brands from a channel and patient journey perspective. In other words we’ll look into demand and supply trends but...
Join us for this important webinar where we will be discuss and analyze the impact of COVID-19 on distributor inventories, downstream inventories, demand, and supply chain omits. We will also be sharing early results on our recent Channel Data Benchmark and Analysis Study. Be...
Join us for this webinar where we will be sharing updated pipeline days-on-hand (DOH) benchmarks and a case study highlighting the improvement in accuracy of Gross-to-Net revenue forecasting when incorporating DOH data and analytics.
Join us for this webinar where we will present the best practices on reaching effective order management to limit a manufacturer’s susceptibility to price speculation and serve as a safeguard against suspicious orders of highly-regulated, controlled drugs.
Join us for this webinar where we will present the best practices on launch readiness, designing optimal contract strategies, challenging and capturing rebate dollars, validating checks and blind spots in chargebacks, and automation benefits of GTN.
Join us for this webinar where We’ll discuss what defines a “bad contract,” how to identify what you need in your contract and what is typically missing, how to effectively renegotiate data contracts and enforce accountability.
Join us for this webinar when we'll present the latest 340B benchmarks and usage trends in critical therapeutic areas: Oncology, Immunology, and Virology (HCV, HBV and HIV). We also will review the latest best practices to prevent duplicate discounts and other potential program violations.
The channels by which patients access therapies continues to evolve and expand. During this webinar, we will walk through case studies on how we have helped manufacturers navigate this challenge and make sure your sales compensation programs are timely and accurate.
Watch Melissa O'Neal, Segment Leader, Distribution, and Sunay Shah, VP of Product Management for our webinar recording introducing the Fall 2019 ICyte Release. Melissa and Sunay demonstrated key new features and functionality, including: Scheduled Reporting, Spotfire X Upgrade, Distribution Contract Management Reporting, Order Management...
Provided by Jen Sharpe, CBI GTN Summit chairperson powered by Revenue Analytics Collaborative Survey Sponsored by IntegriChain and CBI.
IntegriChain has helped a number of leading specialty brands across therapeutic areas develop and implement a specialty data & analytics strategy for launch. We've consolidated a list of best practices including SP data contracting, de-identification/tokenization, data quality, data warehouse integration, and patient journey analytics...
This webinar discusses some of the new pricing laws coming online as well as adjustments to consider in your compliance monitoring framework. Webinar attendees will receive information on key legislative trends, understand implications on pricing and launch programs and review key elements of a...
An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language, determine the metric outputs that are possible. This post looks at how the right specialty...
IntegriChain is utilizing AI and machine learning to develop risk score models that will allow Field Reimbursement Managers (FRMs) and similar functions to proactively intervene on behalf of patients who are likely to experience roadblocks in their journey -- before the roadblocks occur. Predictive...
In 2018, the US FDA approved 63 novel drugs and biologics—and a staggering 44 of the approved products are considered specialty. The prevalence of specialty products launching and progressing through the development pipeline is giving rise to a nearly equal number of Patient Support...
The quality of status and sub-status data reported by SPs is an ongoing challenge that limits the actionability of data specialty brands have contracted to receive. Clearly, poor data quality limits the level of insights that analytics can surface for key stakeholders. Simply cleansing...
This webinar takes a deep dive into analytics that identify highlight (and predict) the drivers of primary and secondary medication non-adherence. We'll explore how diagnostic insights can help your teams identify and act on the patient journey barriers that delay therapy initiation and negatively...
Please join us for this session in our Access Insights webinar series exploring the challenges of calculating total inventory pipeline for specialty products. In this webinar, we will be joined by a few of IntegriChain's top Subject Matter Experts who will discuss their first...
Poor quality SP data is preventing brands from taking actions that help patients start on therapy faster and stay on therapy longer. What are the steps required to improve data quality and achieve true patient access visibility? Through our work with leading specialty brands...
The Roadmap to Launch webinar is a comprehensive countdown of the key gross-to-net (GTN) milestones your team needs to achieve as you prepare for launch. During this webinar we'll share specific insights from companies like yours to highlight different approaches to the most complex...
Please join us for the first session in our webinar series exploring the benefits, trends, and winning strategies for Gross-to-Net Automation. We begin this series by reiterating best practices and exploring modern options for automating and optimizing channel distribution datasets when setting pipeline and...
Join us for the first in a series of webinars focused on Access Launch Readiness. We’ll start this series with our new daVIZta colleagues for a great entry point for emerging Life Sciences manufacturers who are planning their launch within the next two years....
Facilitating patient access to prescribed specialty therapeutics continues to be a challenge in a difficult managed care environment. Patients need help navigating obstacles that delay therapy initiation, such as prior authorization and rising out-of-pocket costs, and cause interruptions in treatment. Field Reimbursement (FRM) teams...
Missing patient status updates, limited granularity, and inaccurate information all contribute to poor patient journey visibility. A lack of insights into each individual patient journey make it exceedingly difficult to manage a specialty brand. How then, can specialty brands cultivate true patient journey insights...
How will you use analytics to measure commercial success and improve patient experience for your specialty brand? An effective specialty data contracting strategy starts at the finish line and works backward. The decisions you make in terms of data fields, sub-status granularity, reporting frequency,...
The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharma manufacturers are now facing increased scrutiny and need a new approach to suspicious order monitoring. In this post, IntegriChain Solutions Principal...
There is broad agreement across the pharmaceutical industry and Congress that that 340B program needs more oversight and statutory change. But with so much congressional paralysis and midterm elections on the horizon, it’s highly unlikely that changes will occur anytime soon. The status quo...
Prior Authorization (PA) is required for nearly all specialty products and is largely responsible for delayed patient initiation. Lengthy PA delays can ultimately result in cancellations for new patient referrals, adherence/persistence problems, and lower patient satisfaction. There are several ways specialty brands can improve...
Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these...
Based on our experience as the access operations team and data platform for more than 100 pharma companies that are launching novel drugs in the US, we've developed a Commercial Readiness Timeline guide--taking you from 12-months pre-launch for readiness to 12-months post-launch for commercialization--that...
Estimating the value of net sales adjustments from a Finance perspective can be very difficult due to a lack of available data and market information. The problem is especially acute before launch and in the first few quarters the product is on the market....
IntegriChain Market Access has been able to leverage subject matter expertise, tools, and techniques to identify between 1.25% and 2.5% of a payers' total rebate spend as non-compliant. In this webinar, our in-house experts John Still and Tina Cullen highlight how two critical compliance...
The expansion of specialty networks to include more pharmacies, and the growing complexity within these networks, is forcing manufacturers to make trade offs as they contract for data critical to understanding and impacting the patient journey. In this webinar, we look at how the...
The list of challenges associated with commercializing a product is long and diverse. Every decision seems to affect patient access to your product and has long-term implications on growth and profitability. Too often manufacturers make commercialization decisions, negotiate agreements, and set prices that aren't...
The need for the type of accountability provided by order management technology has never been greater. Price Transparency legislation passed in a handful of states in 2017, including California. Additional states are working on their own bills. These laws have the potential to encourage...
Multiple factors are challenging patients as they seek access to innovative brands at the retail pharmacy. Complicated payer/plan policy restrictions, including prior authorizations, often delay initiation of therapy. Escalating out-of-pocket costs are another obstacle patients must navigate. This webinar highlights how IntegriChain Retail Analytics...
A manufacturer had historically based Managed Care pricing decisions on highly subjective information and emotion rather than historical data on customer and contract performance. Limited and inaccurate data led to impromptu “how are we doing?” check-in calls. As a result, members of the Pricing...
A disconnect existed between the contract negotiation business function and the contract analyst business function. The belief was that contract performance was not meeting expectations set at the outset of the agreement. We applied a Rational Pricing methodology to help the manufacturer determine if...
As the industry refocuses on more innovative, expensive specialty drugs and channel designs shift, however, manufacturers are growing increasingly concerned with the 340B Drug Discount Program. Analytics will help manufacturers in their quest to discern how and where products are discounted.
Manufacturers know that ensuring product availability is very difficult, especially when product distribution is so expensive. Further complicating matters, sales do not equal demand, leading to a real commerce optimization problem within the demand network.
Pharmaceutical manufacturers continue to struggle with ensuring product availability, controlling distribution cost, and increasing forecast accuracy. This is often because they are using outdated or constrained legacy platforms. In this ebook, learn how three of our customers moved away from disparate systems to IntegriChain’s...
The latest release of the IntegriChain channel management cloud offers mobile user access and near real-time demand sensing to maximize the accessibility and value of channel data through the life sciences supplier enterprise.
IntegriChain Director of Solution Engineering Dave Weiss and guest speaker Michael Townsend, IDC Health Insights Research Manager, Life Sciences Business Systems Strategies explore the changing breadth of the 340B Discount Drug Program and the insights offered in the Health Resources and Services Administration’s (HRSA’s) recently released mega-guidance, including results...
IntegriChain and Lora Cecere, Founder & CEO of Supply Chain Insights, take a deep dive into the new “outside-in” methodology of using actual channel data to make informed order decisions. Lora focuses on how suppliers can use advanced analytics to sense order flows and...
In this webinar, we explore best practices for estimating inventory when calculating gross-to-net to eliminate gross overstatements or understatements of pipeline liabilities that do not triangulate well with other commercial commerce datasets. Attendees will learn about best practices for using auditor-approved downstream inventory data...
Builder radically improves the actionability of channel analytics, driving down the cost of total ownership of wholesaler and specialty data sources while maximizing the value of manufacturer investments in data agreements. This webinar covers merging disparate data sources into one report or visualization, manipulating...
Manufacturers know that ensuring product availability is very difficult, especially when product distribution is so expensive. Further complicating matters, sales do not equal demand, leading to a real commerce optimization problem within the demand network. Download The Value of 1% White Paper to explore...
In today’s era of Pay-for-Performance agreements and lean channel inventory, pharmaceutical manufacturers want to know how to better align product availability with the overall cost of distribution. The answer can be found in a new approach to trade data utilization called Daily Business Management....
As distribution service agreements evolve over time, manufacturers must have the ability to run what-if analyses on actual scorecard data to analyze the overall effect various changes under consideration would have on trade partner payments. In this post, we look at how Distributor Contract...
IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory....
